LON:PRM Proteome Sciences (PRM) Share Price, News & Analysis → why 99.94% won’t make you money (From Prosper Trading Academy) (Ad) Free PRM Stock Alerts GBX 4.19 -0.02 (-0.48%) (As of 06/17/2024 ET) Add Compare Share Share Today's Range 3.64▼ 4.1950-Day Range 2.82▼ 4.7052-Week Range 2.65▼ 8.79Volume22,002 shsAverage Volume188,664 shsMarket Capitalization£12.37 millionP/E RatioN/ADividend Yield6.17%Price TargetN/A Stock AnalysisStock AnalysisChartCompetitorsHeadlinesStock AnalysisChartCompetitorsHeadlines Get Proteome Sciences alerts: Email Address Ad Behind the MarketsAre you prepared for a Chinese "invasion?"Recently declassified documents show that while the U.S has been distracted in the Middle East... China had been studying our every move... And preparing themselves for not only an armed conflict with the United StatesHere are 4 steps you can take RIGHT NOW >>> About Proteome Sciences Stock (LON:PRM)Proteome Sciences plc provides contract research services for the identification, validation, and application of protein biomarkers in the United States, the United Kingdom, European Union, and internationally. The company offers TMT LC-MS2, a standard method for analyzing cells and tissues when no phosphopeptide enrichment is required; TMT LC-MS3, a standard method for biomarker discovery in plasma and other samples where quantitative accuracy is a factor; SysQuant, provides an analysis of protein activity across regulatory and signaling pathways; and TMTcalibrator, analyzes where diseased or treated tissue can be analyzed in parallel with peripheral fluids. It also provides top 14 and top 65 super depletion of proteins from serum and plasma; selective reaction monitoring (SRM) and parallel reaction monitoring (PRM) based biomarker assay development; SRM assay, a targeted mass spectrometry assay format for the routine measurement of biomarkers; and TMT SRM, a targeted assay format that enables the rapid validation of biomarker candidates. The company serves its products to pharmaceutical and biotechnology companies, and academic research institutes. The company was incorporated in 1993 and is based in Cobham, the United Kingdom.Read More PRM Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart PRM Stock News HeadlinesMay 2, 2024 | msn.comProtein profiling reveals impact of aging and resistance training on skeletal muscle proteomeApril 27, 2024 | finance.yahoo.comProteome Sciences Full Year 2023 Earnings: UK£0.008 loss per share (vs UK£0.004 profit in FY 2022)April 11, 2024 | msn.comConsumer microbiome startup Seed Health is rolling its profits into an AI science moonshotMarch 22, 2024 | msn.comResearchers analyze how the proteome of specific brain cells changes as we ageMarch 20, 2024 | uk.finance.yahoo.comProteome Sciences PLC (PRM.AQ)January 22, 2024 | finance.yahoo.comIf EPS Growth Is Important To You, Proteome Sciences (LON:PRM) Presents An OpportunityJanuary 4, 2024 | proactiveinvestors.com.auProteome Sciences opens lab in San DiegoJanuary 2, 2024 | proactiveinvestors.comProteome Sciences opens lab in San Diego’s biotech hubOctober 2, 2023 | lse.co.ukProteome Sciences sees shares surge on SysQuant service launchAugust 25, 2023 | uk.investing.comFTSE 100 Live: Stocks extend gains ahead of Jackson HoleAugust 25, 2023 | marketwatch.comProteome Sciences Shares Fall After Swing to Loss on Higher CostsAugust 15, 2023 | finance.yahoo.comWe Ran A Stock Scan For Earnings Growth And Proteome Sciences (LON:PRM) Passed With EaseMay 17, 2023 | marketwatch.comProteome Sciences Says It Is Well-Positioned for 2023 GrowthMay 12, 2023 | lse.co.ukProteome Sciences expanding to US with San Diego facilityApril 29, 2023 | fool.co.ukProteome SciencesMarch 8, 2023 | finance.yahoo.comDoes Proteome Sciences (LON:PRM) Deserve A Spot On Your Watchlist?January 25, 2023 | finanznachrichten.deAdvanced Proteome Therapeutics Corp.: Advanced Proteome Therapeutics Announces Its Proposed Plan of ArrangementAugust 30, 2022 | finance.yahoo.comHere's Why Proteome Sciences (LON:PRM) Has Caught The Eye Of InvestorsAugust 5, 2022 | lse.co.ukProteome reaches milestone in launch of proteomics serviceMay 17, 2022 | lse.co.ukProteome Sciences maintains strong order bookDecember 14, 2021 | apnews.comBiognosys Expands Co-Marketing Agreement with Global Life Science Leader to Advance ProteomicsDecember 7, 2021 | finance.yahoo.comHere's Why I Think Proteome Sciences (LON:PRM) Might Deserve Your Attention TodayNovember 15, 2021 | finance.yahoo.comThermo Fisher Scientific Advances Proteomics Through Select Collaborations and New Analytical Instrument SolutionsSeptember 6, 2021 | finance.yahoo.comA Look At The Fair Value Of Proteome Sciences plc (LON:PRM)See More Headlines Receive PRM Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Proteome Sciences and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings8/10/2020Today6/18/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeLON SectorMedical Industry Diagnostics & Research Sub-IndustryN/A Current SymbolLON:PRM CUSIPN/A CIKN/A Webwww.proteomics.com Phone+44-20-70432116FaxN/AEmployees35Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)GBX (0.01) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income£-2,440,000.00 Net Margins-48.59% Pretax MarginN/A Return on EquityN/A Return on Assets-8.48% Debt Debt-to-Equity RatioN/A Current Ratio0.33 Quick Ratio0.37 Sales & Book Value Annual Sales£5.03 million Price / Sales2.46 Cash FlowGBX 1.12 per share Price / Cash Flow3.73 Book ValueGBX (1) per share Price / Book-4.19Miscellaneous Outstanding Shares295,180,000Free FloatN/AMarket Cap£12.37 million OptionableNot Optionable Beta-0.03 20 Stocks to Sell NowMarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio? Find out by clicking the link below.Get This Free Report Key ExecutivesDr. Mariola Sohngen (Age 63)CEO & Executive Director Comp: $261kMr. Abdelghani Omari (Age 48)CFO & Director Comp: $212kDr. Ian H. Pike (Age 60)Chief Scientific Officer & Executive Director Comp: $245kMr. Richard Paul Dennis (Age 66)Chief Commercial Officer & Executive Director Comp: $207kVictoria Joanna BirseCompany SecretaryKey CompetitorsANGLELON:AGLVerici DxLON:VRCIYourgene HealthLON:YGENAbingdon HealthLON:ABDXGENinCodeLON:GENIView All Competitors PRM Stock Analysis - Frequently Asked Questions How have PRM shares performed in 2024? Proteome Sciences' stock was trading at GBX 4.53 on January 1st, 2024. Since then, PRM stock has decreased by 7.5% and is now trading at GBX 4.19. View the best growth stocks for 2024 here. How were Proteome Sciences' earnings last quarter? Proteome Sciences plc (LON:PRM) posted its earnings results on Monday, August, 10th. The company reported ($0.17) EPS for the quarter. What other stocks do shareholders of Proteome Sciences own? Based on aggregate information from My MarketBeat watchlists, some companies that other Proteome Sciences investors own include ValiRx (VAL), boohoo group (BOO), Mondi (MNDI), Petrofac (PFC), Lloyds Banking Group (LLOY), Falanx Group (FLX), Quanterix (QTRX), Centrica (CNA), CyanConnode (CYAN) and Eckoh (ECK). How do I buy shares of Proteome Sciences? Shares of PRM stock and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.Compare Top Brokerages Here. This page (LON:PRM) was last updated on 6/18/2024 by MarketBeat.com Staff From Our PartnersBigger Than NVIDIA?With NVIDIA flying high, everyone is looking for the next breakout stock. But right now... There's only ...Behind the Markets | SponsoredBeta testers blew this thing upThis AI trading tool is probably unlike anything you've ever seen before… It scans the entire market and fi...Prosper Trading Academy | SponsoredUnexpected twist to Trump’s trialUnexpected Twist to Trump's Trial Most folks sense there's more to the Trump trial than meets the eye. B...Stansberry Research | SponsoredAI's Next Magnificent SevenThe Original Magnificent Seven Produced 16,894% Average Returns Over 20 Years.The Oxford Club | SponsoredThe #1 Crypto That You Don’t Own… YetThere’s all kinds of “signals” to follow when investing in cryptos. But there’s one signal you should pay a...Crypto 101 Media | SponsoredInflation Is Robbing You Blind! Here’s How to Fight Back!Quietly, inflation has reduced your purchasing power by 29.4% since 2014. So something that cost $100 in 20...American Alternative | SponsoredElon Musk: THIS will be bigger than TeslaIf you missed out on crypto, this could be your second chance. The AI “wealth window” is opening now, but you ...Paradigm Press | SponsoredMissed NVDA? Buy this AI stock NOWAfter Nvidia's record-breaking earnings surge, Wall Street is now selling the stock at the fastest pace in sev...Chaikin Analytics | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Proteome Sciences plc Please log in to your account or sign up in order to add this asset to your watchlist. Share Proteome Sciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.